TCR1188-ABC Cells therapy (University Of Pennsylvania)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTCR1188-ABC Cells therapy (University Of Pennsylvania)
Drug Alias NameTCR1188-ABC
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulatorsLeukocyte immunoglobulin-like receptor subfamily B member 2 modulators
TargetsGTPase KRasLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A